Phase 3 Cardiotoxicity Clinical Trials
4 recruitingPhase 3
What is a Phase 3 trial?
Phase 3 trials compare the new treatment against the current standard of care in large groups, often hundreds to thousands of participants. Successful Phase 3 results are typically required for regulatory approval.
Showing 1–4 of 4 trials
Recruiting
Phase 3
Empagliflozin in the Prevention of Cardiotoxicity in Cancer Patients Undergoing Chemotherapy Based on Anthracyclines
Cardiotoxicity
Maria Sklodowska-Curie National Research Institute of Oncology220 enrolled2 locationsNCT05271162
Recruiting
Phase 3
S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity
Recurrent Breast CarcinomaStage IV Breast Cancer AJCC v6 and v7Cardiotoxicity+2 more
SWOG Cancer Research Network491 enrolled590 locationsNCT03418961
Recruiting
Phase 3
Cardioprotection on Chemotherapy-Induced Cardiotoxicity
Cardiotoxicity
Ain Shams University30 enrolled2 locationsNCT06853951
Recruiting
Phase 3
The Use of Shengmai San to Prevent Anthracycline Sequential Trastuzumab Therapy Related Cardiac Toxicity
Cardiotoxicity Induced by Drug Therapy for Breast Cancer
Zhejiang Cancer Hospital276 enrolled1 locationNCT06214195